360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Homozygous

Type: Keyphrase

Name: Homozygous

First reported 11 hours ago - Updated 11 hours ago - 1 reports

Motley Fool

Too Many Questions Make This Thursday Mover a Sell

Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Aegerion Pharmaceuticals had previously reported that patient cost would be between $200,000 and $300,000 annually ... [Published Motley Fool - 11 hours ago]

Entities: Aegerion Pharmaceuticals Inc, Motley Fool, Patient, Brian Nichols

First reported May 16 2013 - Updated May 17 2013 - 1 reports

Aegerion Pharmaceuticals Inc

Aegerion stock soars on price boost for cholesterol drug, Juxtapid

Shares of Aegerion Pharmaceuticals (Nasdaq:AEGR) rose more than 30 percent to $61.10 as of 3:45 p.m. Thursday after the company said it would increase the price of Juxtapid, its drug which was approved by the U.S. Food and Drug Administration in December ... [Published Boston Business Journal - May 16 2013]

Entities: Aegerion Pharmaceuticals Inc, Cholesterol, Drugs

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Black Brings the Green

"I’ve always ranched, but for years I ranched for other people,” chuckled Ray Marchant of Howell County.That’s how he explained his experience when he worked for Foster Farms raising their breeder turkeys. “We moved here from California when Ray retired,” ... [Published Ozarks Farm & Neighbor - May 16 2013]

Entities: Cattle, Genetics, Homozygous

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Mucopolysaccharidosis Type VI: A Predominantly Cardiac Phenotype Associated With Homozygosity for p.R152W Mutation in the ARSB Gene

Mucopolysaccharidosis type VI (MPS VI) is a rare lysosomal, autosomal recessive storage disorder caused by deficient activity of N‐acetylgalactosamine‐4‐sulfatase (ARSB). Approximately, 140 ARSB gene mutations have been identified; however, most are private ... [Published Bionity.com - May 09 2013]

Entities: Mucopolysaccharidosis, Phenotype, Mutation, Homozygous, Patient

First reported May 07 2013 - Updated May 08 2013 - 2 reports

Isis Pharmaceuticals Inc

Isis Pharma selling 9 million shares

CARLSBAD — Isis Pharmaceuticals said Tuesday it plans to sell up to 10.35 million shares of stock. That would bring Isis about $225 million at Tuesday's closing price of $21.89 per share.Isis did not say it it planned to do with the money, and unlike ... [Published U-T San Diego - May 08 2013]

Entities: Isis Pharmaceuticals Inc, Kynamro, Familial Hypercholesterolemia, Homozygous

First reported May 01 2013 - Updated May 01 2013 - 1 reports

A novel intellectual disability syndrome caused by GPI anchor deficiency due to homozygous mutations in PIGT

PurposeTo delineate the molecular basis for a novel autosomal recessive syndrome, characterised by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic finding ... [Published Journal of Medical Genetics - May 01 2013]

Entities: Homozygous, mutations, Disability

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Breeding against Oedema disease in Switzerland

It’s a matter of genetics: Not all pigs are susceptible to oedema disease. What happens if a breeding programme could make all piglets resistant to oedema disease? A promising initiative in Switzerland embarked on this mission.Oedema disease is a well-known ... [Published Pig Progress - May 01 2013]

Entities: Homozygous, Genotype, Escherichia Coli (E. Coli), Edema

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Genome-Wide Association Studies Identify Two Novel BMP15 Mutations Responsible for an Atypical Hyperprolificacy Phenotype in Sheep

Some sheep breeds are naturally prolific, and they are very informative for the studies of reproductive genetics and physiology. Major genes increasing litter size (LS) and ovulation rate (OR) were suspected in the French Grivette and the Polish Olkuska ... [Published Bionity.com - May 01 2013]

Entities: Genome-wide Association Studies, Phenotype, Homozygous, mutations

First reported Apr 30 2013 - Updated Apr 30 2013 - 2 reports

Fast-tracking development of homozygous transgenic cereal lines using a simple and highly flexible ...

A crucial step in the evaluation of newly produced transgenic plants is the selection of homozygous plants. Here we describe an efficient and highly flexible real-time PCR-based method for the development of homozygous lines in plant models with complex ... [Published 7thSpace - Apr 30 2013]

Entities: Homozygous, Transgenic, Transgene, Polymerase Chain Reaction

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Intellectual disability associated with a homozygous missense mutation in THOC6

We recently described a novel autosomal recessive neurodevelopmental disorder with intellectual disability in four patients from two related Hutterite families. Identity-by-descent mapping localized the gene to a 5.1 Mb region at chromosome 16p13.3 containing ... [Published 7thSpace - Apr 26 2013]

Entities: Homozygous, Disability, Messenger RNA, Chromosome, Mutant

First reported Apr 24 2013 - Updated Apr 24 2013 - 2 reports

Amgen Earnings Call Insights: EPO Franchise and Healthcare Reform Impact

Amgen ( NASDAQ:AMGN ) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.EPO FranchiseRobyn Karnauskas – Deutsche Bank : So, first up, you commented about the EPO franchise. Can you comment ... [Published Wall St. Cheat Sheet - Apr 24 2013]

Entities: Robert A. Bradway, Amgen Inc, Joshua Schimmer, Health Care Reform

First reported Apr 20 2013 - Updated Apr 20 2013 - 2 reports

3 Healthcare Stock Stories For Weekend Investment Wellness

Pluristem Therapeutics ( NASDAQ:PSTI ): Closing price $2.98Pluristem reported that it is expanding its presence in the orthopedic and sports medicine markets with plans to begin a Phase I clinical trial, through which to study the safety and efficacy ... [Published Wall St. Cheat Sheet - Apr 20 2013]

Entities: Vertex Pharmaceuticals Inc, Cystic Fibrosis, Health Care, HIV/AIDS, Assay

Quotes

According to the news editors, the research concluded: "These data indicate that VDR contributes to the control of AD, e g. by regulation of the epidermal barrier function and/or local immune response."

Recent Findings from University of Kiel Has Provided New Information about Dermatology [Published NewsRX - May 17 2013]

"I’ve always ranched, but for years I ranched for other people,” chuckled Ray Marchant of Howell County."

Black Brings the Green [Published Ozarks Farm & Neighbor - May 16 2013]

...According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Insulin resistance (IR) is a complex disorder caused by an interplay of both genetic and environmental factors. Recent studies identified a significant interaction between body mass index (BMI) and the rs1800795 polymorphism of the interleukin-6 gene that influences both IR and onset of type 2 diabetes mellitus, with obese individuals homozygous for the C allele demonstrating the highest level of IR and greatest risk for type 2 diabetes mellitus."

Findings from Brigham and Women's Hospital and Harvard University School of Medicine in Diabetes ... [Published NewsRX - May 11 2013]

According to the news reporters, the research concluded: "Growth hormone and estrogen treatment may be of some benefit, respectively, to growth retardation and breast hypoplasia, though further studies in this patient group are needed."

New Data from Radboud University Nijmegen Medical Center Illuminate Findings in Human Genetics [Published NewsRX - May 10 2013]

More Content

sort by: Date \| Relevance
Too Many Questions Make This Thursday Mover a Sell [Published Motley Fool - 11 hours ago]
Uphoria! A half-arabian tops all [Published HorseTalk.co.nz - 21 hours ago]
A novel desmin mutation leading to autosomal re... [Published Journal of Medical Genetics - May 18 2013]
4 Companies With Extreme Price Charts And High ... [Published Seeking Alpha - May 17 2013]
Ubiquitin System Awry in Ataxia, Intellectual D... [Published Alzheimer Research Forum - May 17 2013]
Financings of the Fortnight Waits For Public In... [Published The IN VIVO Blog - May 17 2013]
Aegerion’s Pricing Power Sends Shares Flying [Published BioMedReports - May 17 2013]
Recent Findings from University of Kiel Has Pro... [Published NewsRX - May 17 2013]
Association between Polymorphisms of the IL-23R... [Published Elites TV - May 17 2013]
Sangamo BioSciences, Inc's Management Presents ... [Published Seeking Alpha - May 16 2013]
Aegerion stock soars on price boost for cholest... [Published Boston Business Journal - May 16 2013]
Black Brings the Green [Published Ozarks Farm & Neighbor - May 16 2013]
ISIS Pharmaceuticals Management Presents at Ban... [Published Seeking Alpha - May 15 2013]
The Drosophila Homologue of the Amyloid Precurs... [Published PLoS Biology - May 15 2013]
International Stem Cell Corporation to Present ... [Published PR inside - May 15 2013]
International Stem Cell Corporation to Present ... [Published Zecco - May 15 2013]
Oxytocin in Brattleboro rats: Increased synthes... [Published Bionity.com - May 15 2013]
Secondary Evolution of a Self-Incompatibility L... [Published PLoS Biology - May 15 2013]
research by Bassem Hassan and colleagues [Published PLoS Biology - May 15 2013]
tPA affects Purkinje neuron development & survi... [Published PNAS - May 15 2013]
ARCA BIOPHARMA, INC. - 10-Q - MANAGEMENT'S DISC... [Published Pharmacy Choice - May 14 2013]
Buyers dust off dry times at Limousin sale [Published Albury Border Mail - May 13 2013]
Global CF therapeutics market: $4.6 billion ind... [Published TransWorldNews - May 12 2013]
Findings from Brigham and Women's Hospital and ... [Published NewsRX - May 11 2013]
New Data from Radboud University Nijmegen Medic... [Published NewsRX - May 10 2013]
Aristaless-Related Homeobox Plays a Key Role in... [Published Elites TV - May 10 2013]
NSW takes top Limo honours [Published Farm Weekly - May 09 2013]
International Stem Cell Corporation to Host Fir... [Published PR inside - May 09 2013]
Iita to Eliminate Vitamin a-Induced Malnutritio... [Published AllAfrica.com - May 09 2013]
Genetic Variation in FADS Genes and Plasma Chol... [Published Elites TV - May 09 2013]

Blogs

sort by: Date \| Relevance
Financings of the Fortnight Waits For Public In... [Published The IN VIVO Blog - May 17 2013] It’s been another IPO-intensive couple of weeks here at FOTF HQ. We keep looking for other things to write about, but sometimes the fastest shave on deadline is with Occam’s razor. Or something like that. We didn't exactly ace our philosophy classes ...
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013] In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ...
Amgen Earnings Call Insights: EPO Franchise and... [Published Wall St. Cheat Sheet - Apr 24 2013] Amgen ( NASDAQ:AMGN ) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.EPO FranchiseRobyn Karnauskas – Deutsche Bank : So, first up, you commented about the EPO franchise. Can you comment ...
Amgen Earnings Call Insights: EPO Franchise and... [Published Wall St. Cheat Sheet - Apr 24 2013] Amgen ( NASDAQ:AMGN ) recently reported its first quarter earnings and discussed the following topics in its earnings conference call. EPO Franchise Robyn Karnauskas – Deutsche Bank: So, first up, you commented about the EPO franchise. Can you ...
3 Healthcare Stock Stories For Weekend Investme... [Published Wall St. Cheat Sheet - Apr 20 2013] Pluristem Therapeutics ( NASDAQ:PSTI ): Closing price $2.98Pluristem reported that it is expanding its presence in the orthopedic and sports medicine markets with plans to begin a Phase I clinical trial, through which to study the safety and efficacy ...

Press Releases

sort by: Date \| Relevance
Treatment with VX-661 and Ivacaftor in a Phase ... [Published Business Wire Health News - Apr 18 2013]
Genzyme and Isis Announce FDA Approval of KYNAM... [Published EON Health & Medicine - Jan 29 2013]
Genzyme and Isis Announce FDA Approval of KYNAM... [Published Business Wire Health News - Jan 29 2013]
FDA Approves Aegerion Pharmaceuticals' JUXTAPID... [Published GlobeNewswire: Acquisitions News - Dec 24 2012]
Genzyme and Isis Provide Update on CHMP Opinion... [Published EON Health & Medicine - Dec 14 2012]